INVO Bioscience, Inc. to Present at Upcoming Industry and Financial Conferences

Business Wire, June 10, 2009

BEVERLY, Mass. -- INVO Bioscience, Inc. (OTC BB: IVOB), a medical device company focused on treatment options for patients diagnosed with infertility, announced today that management will be presenting at the European Society of Human Reproduction and Embryology (“ESHRE”) annual meeting to be held in Amsterdam, Netherlands on June 28-July 1, 2009, and at the 2009 RedChip Small-Cap Investor Conference to be held on June 16, 2009 in Fort Lauderdale, Fla. INVO Bioscience’s patented product, the INVOcell, allows for vaginal incubation of eggs, sperm and early embryo development during the infertility treatment process.

ESHRE’s annual meeting is the forum where more than 6,000 of the world’s leading experts in reproductive medicine gather to give the first public presentation of their latest research findings and to discuss issues that are presenting lawmakers and ethicists with some of the most challenging problems and difficult decisions currently facing society.

The 2009 RedChip Small-Cap Investor Conference, which is being held in conjunction with Collaborative Communications Summit’s Health Information Technology Conference, will feature a dedicated presentation track for healthcare technology companies at the Hilton Fort Lauderdale Marina (1881 SE 17th Street Causeway).

RedChip investor conferences are a nationally known forum for emerging small-cap companies to present their stories before hundreds of retail brokers, institutional brokers, fund managers, portfolio managers, accredited investors and research analysts whose disciplined focus towards the small-cap markets represents their core investment strategies.

INVO Bioscience’s presentation will also be webcast live via http://www.redchip.com. Participating investors will have the opportunity to meet one-on-one with the CEOs of presenting companies, while thousands of investors from across the world will view the conference online, watching the presentations live at RedChip.com on the day of the conference. In addition, RedChip TV will be on site conducting interviews with CEOs, and these interviews will be archived for viewing at RedChip.com one week following the event.

“Our presentation at the ESHRE annual meeting is critical as we continue to open INVO Centers and offer the INVO procedure at In Vitro Fertilization (IVF) centers around the world,” said INVO Bioscience CEO Kathleen Karloff. “Our goal is to offer INVO globally as a simpler and more affordable solution to address infertility. We realize that now is the most opportune time to speak to industry opinion leaders as well as the investment community to foster new relationships.”

The INVOcell has already received European CE Mark approval and began selling units in late 2008 in select countries outside the United States. INVO Bioscience, Inc. is pursuing U.S. Food and Drug Administration clearance for the INVOcell.

About the INVO Procedure

The INVOcell and INVO Procedure combine a natural or mild (mild medication) stimulation infertility treatment cycle, using lower amounts of injectable fertility hormones than used in traditional IVF (in vitro fertilization), with intra-vaginal incubation (IVC) of sperm and eggs. Following standard egg retrieval, the woman’s eggs (oocytes) are combined with sperm in the INVOcell, a small device, which is then sealed and placed in the woman’s vaginal cavity to incubate for three days. When the INVOcell is removed, the anticipated one to two developing embryos are transferred directly into the woman’s uterine cavity, where implantation and continued pregnancy can take place.

The company has received European CE Mark approval for the INVOcell and, in 2008, launched the product in select countries outside the U.S. The company is also pursuing U.S. Food and Drug Administration 510(k) clearance for the INVOcell.

About INVO Bioscience

INVO Bioscience (IVOB) is a medical device company, headquartered in Beverly, Massachusetts, focused on creating simplified, lower cost treatment options for patients diagnosed with infertility. The company’s lead product, the INVOcell, is a novel medical device used in infertility treatment that enables egg fertilization and early embryo development in the woman’s vaginal cavity. The company was founded by Claude Ranoux, MD, a noted expert in the field of reproductive health, infertility and embryology. For more information, please visit www.invobioscience.com.

This release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements regarding our expected future financial position, results of operations, cash flows, financing plans, business strategies, products and services, competitive positions, growth opportunities, plans and objectives of management for future operations, as well as statements that include words such as "anticipate," "if," "believe," "plan," "estimate," "expect," "intend," "may," "could," "should," "will," and other similar expressions are forward-looking statements. All forward-looking statements involve risks, uncertainties and contingencies, many of which are beyond our control, which may cause actual results, performance, or achievements to differ materially from anticipated results, performance, or achievements. Factors that may cause actual results to differ materially from those in the forward-looking statements include those set forth in our filings at www.sec.gov. We are under no obligation to (and expressly disclaim any such obligation to) update or alter our forward-looking statements, whether as a result of new information, future events or otherwise.